Nicole Houston

Nicole Houston

Auto-generated profile, based on publicly available information

Nicole Houston

Women's Malignancies Branch, Center for Cancer Research, NCI, NIH

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
DGDaniel S. Green
Daniel S. Green
FNFranklin Ning
Franklin Ning
ADAnna Duemler
Anna Duemler
TMTimothy G. Myers
Timothy G. Myers
KTKathryn Trewhitt
Kathryn Trewhitt
CAChristina Annunziata
Christina Annunziata
Purpose: Ovarian cancer is the most lethal gynecologic cancer and intrinsically resistant to checkpoint immunotherapies. We sought to augment innate immunity, building on previous work with IFNs and monocytes. Patients and Methods: Preclinical experiments were designed to define the mechanisms of cancer cell death mediated by the combination of IFNs α and γ with monocytes. We translated these preclinical findings into a phase I trial of autologous IFN-activated monocytes administered intraperitoneally to platinum-resistant or -refractory ovarian cancer patients. Results: IFN-treated monocytes induced caspase 8–dependent apoptosis by the proapoptotic TRAIL and mediated by the death receptors 4 and 5 (DR4 and DR5, respectively) on cancer cells. Therapy was well tolerated with evidence of clinical activity, as 2 of 9 evaluable patients had a partial response by RECIST criteria, and 1 additional patient had a CA-125 response. Upregulation of monocyte-produced TRAIL and cytokines was confirmed in peripheral blood. Long-term responders had alterations in innate and adaptive immune compartments. Conclusions: Given the mechanism of cancer cell death, and the acceptable tolerability of the clinical regimen, this platform presents a possibility for future combination therapies to augment anticancer immunity. See related commentary by Chow and Dorigo, p. 299

16 February 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
SJSarah Jenkins
Sarah Jenkins
WZWei Zhang
Wei Zhang
SSSeth M. Steinberg
Seth M. Steinberg
DNDarryl Nousome
Darryl Nousome
NHNicole Houston
Nicole Houston
AZAlexandra S. Zimmer
Alexandra S. Zimmer
Purpose: Preclinical data showed that prophylactic, low-dose temozolomide (TMZ) significantly prevented breast cancer brain metastasis. We present results of a phase I trial combining T-DM1 with TMZ for the prevention of additional brain metastases after previous occurrence and local treatment in patients with HER2+ breast cancer. Patients and Methods: Eligible patients had HER2+ breast cancer with brain metastases and were within 12 weeks of whole brain radiation therapy (WBRT), stereotactic radiosurgery, and/or surgery. Standard doses of T-DM1 were administered intravenously every 21 days (3.6 mg/kg) and TMZ was given orally daily in a 3+3 phase I dose escalation design at 30, 40, or 50 mg/m2, continuously. DLT period was one 21-day cycle. Primary endpoint was safety and recommended phase II dose. Symptom questionnaires, brain MRI, and systemic CT scans were performed every 6 weeks. Cell-free DNA sequencing was performed on patients’ plasma and CSF. Results: Twelve women enrolled, nine (75%) with prior SRS therapy and three (25%) with prior WBRT. Grade 3 or 4 AEs included thrombocytopenia (1/12), neutropenia (1/12), lymphopenia (6/12), and decreased CD4 (6/12), requiring pentamidine for Pneumocystis jirovecii pneumonia prophylaxis. No DLT was observed. Four patients on the highest TMZ dose underwent dose reductions. At trial entry, 6 of 12 patients had tumor mutations in CSF, indicating ongoing metastatic colonization despite a clear MRI. Median follow-up on study was 9.6 m (2.8–33.9); only 2 patients developed new parenchymal brain metastases. Tumor mutations varied with patient outcome. Conclusions: Metronomic TMZ in combination with standard dose T-DM1 shows low-grade toxicity and potential activity in secondary prevention of HER2+ brain metastases.

18 September 2017 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
AZA. Zimmer
A. Zimmer
CPCody Peer
Cody Peer
LCL. Cao
L. Cao
EKE. Kohn
E. Kohn
SLStan Lipkowitz
Stan Lipkowitz
JLJ-M. Lee
J-M. Lee
Background: Recent data showed a PARP inhibitor, O and a VEGFR1-3 inhibitor, C together are clinically superior to O alone in recurrent platinum-sensitive ovarian cancer (OvCa). We hypothesized reduced VEGF signaling by C and DNA damage by O may complement anti-tumor activity of immune checkpoint blockade, D. We previously reported the safety data and RP2D of D in combination with O or C. We now report RP2D and PK/PD data of the D+O+C therapy (NCT02484404).

25 November 2025
Verified
Other
Open access
SJSarah Jenkins
Sarah Jenkins
WZWei Zhang
Wei Zhang
SSSeth M. Steinberg
Seth M. Steinberg
DNDarryl Nousome
Darryl Nousome
NHNicole Houston
Nicole Houston
AZAlexandra S. Zimmer
Alexandra S. Zimmer
Supplemental Fig. 4. Histogram illustrating ERBB2 relative copy number in plasma and CSF cfDNA samples from 12 patients during their T samples from 12 patients during their Tsamples from 12 patients during their T samples from 12 patients during their T-DM1/TMZ combination therapy.


14 April 2023
Verified
Other
Open access
SJSarah Jenkins
Sarah Jenkins
WZWei Zhang
Wei Zhang
SSSeth M. Steinberg
Seth M. Steinberg
DNDarryl Nousome
Darryl Nousome
NHNicole Houston
Nicole Houston
AZAlexandra S. Zimmer
Alexandra S. Zimmer
Supplemental Fig. 3. ERB-B-2 Status of Patients.